Recently, Zhu et al. investigated the application of [68Ga]Ga-NOTA-NY104, a small-molecule CAIX-targeting PET agent with an acetazolamide core and NOTA as a chelator, in a ccRCC tumour model and in patients with diagnosed or suspected ccRCC. Here, CA9 is linked to neoplasm.